Clinical Study Of 80 Cases Type 2 Diabetic Nephropathy Treated By Puerarin

At present, Diabetes mellitus(DM) is a group of metabolic diseases, whose incidence is increasing year after year with the development of the economy. Primary long-term impairments of diabetes to human body are dysfunction and failure of various organs. Diabetic nephropathy (DN) is one of major chronic complications, In patients with diabetes, complications from DN are a major cause of death. Studies showed an incidence of 47.66 cases of DN per 100 every year. The incidence of DN in Chinese patients with diabetes is increasing. DN is a major cause of end-stage renal disease the same as other developed countries in the 21 century. Once patients with diabetes develop clinical renal disease, DN is manifested by proteinuria. Subseqently, When kidnal function declines, patients may dovelop end-stage renal disease. diabetes is the first causing factor of ESRD, accounting for 40 cases per 100 according to the statistic materials from the United States renal disease system. No more effective therapeutic measures can reduce the pathogenesis and deterioration of DN and investigating its mechanisms and preventive measures is our main topic in treating the end-stage renal disease at present. Although the pathogenesis of diabetic nephropathy having been studied, whose mechanism focusing on metabolic disorder theory has not been disclosed completely. And there were many studies from domestic and foreign investigations had showed therelationship between a number of risk factors, such as high glucose in blood and hypertension and metabolism disorder of lipid and abnormal expression of genes and genetic factor, and the like. The degree of renal function damage is positive correlation. Puerarin shows obvious effects in clinical treatment in big hospitals in our country, it presents light side-effects in drug reaction. Puerarin is a inhibitor of AR, Research has demonstrated puerarin reduce the AGEs of diabetic patients, it can inhibit its path of poly-alchohol acid, reduce renal disease injure degree; it can regulate the balance of TXA2 and PGI2, it can decrease the platelet viscosity and aggregation, it have many actions on distending coronary and improving micro-circulation. This indicated that puerarin have many other actions for DN, especially in decreasing albuminuria in early stage of diabetic nephropathy. it can decrease the platelet viscosity and aggregation. Recent studies have found that it has obviously beneficial effects of puerarin on treatment of DN, it can be used to treat type 2 diabetic nephropathy by puerarin safely and effectively, it has comparatively high value of clinical application. we analize and investigate the role of puerarin injection in treating 80 cases of type 2 diabetic nephropathy in clinical treatment from April. 2005 to April. 2007.Objective: To investigate the effects of puerarin injection on diabetic nephropathy (DN).Methods: Comparing forty cases treated by puerarin group withforty cases in control group, and observing the effect of puerarin injection on UAE,BUN,Cr,FBG,2hBG,FINS,TC,TG,LDL,HDL,HbA1c,TC,TG,LDL,HDL and Hemorheology.Results:In treatment group, FBG,UAE,BUN,Cr,FBG,FINS,LDL,HbA1c,LDL decreased markedly; HDL increased markedly(p<0.01); hemorheology improved evidently.Conclusions: Puerarin injection has a good effect on DN. it can be used to treat type 2 diabetic nephropathy by puerarin safely and effectively, it has comparatively high value of clinical application.